Company intelligence / Profile preview

HiST Pharma

Ownership: Private
Development stage: Other

Overview

HiST Pharma's TC Cream demonstrated superior efficacy over the vehicle in its Phase IIb clinical study (NCT03372811) under an 8-week regimen, with an excellent safety and tolerability profile. The FDA has approved the initiation of a Phase III clinical trial for TC Cream to treat psoriasis vulgaris.[1][2]

Therapeutic areas: Dermatology
Modalities: Botanical small molecules
Industry: Biotech

Drug pipeline

1 asset

TC Cream

Partnerships

Planning global licensing strategy with biotech pharma partners

Beyond the preview

Go deeper on HiST Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HiST Pharma.